Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)

• Company Description    CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $3.43 Daily Weekly Monthly 20 Day Moving Average: 330,109 shares Shares Outstanding: 62.75 (millions) Market Capitalization: $215.24 (millions) Beta: 0.27 52 Week High: $7.75 52 Week Low: $2.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.14% -13.06% 12 Week 10.29% 7.15% Year To Date -44.05% -50.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 TALCOTT AVENUE SUITE 201 - WATERTOWN,MA 02472 USA ph: 617-651-8867 fax: - ir@camp4tx.com http://www.camp4tx.com

• General Corporate Information    Officers Josh Mandel-Brehm - President; Chief Executive Officer and Director Douglas Williams - Chairman of the Board Kelly Gold - Chief Financial Officer Michael Higgins - Director Steven Holtzman - Director Peer Information CAMP4 Therapeutics Corporation (CORR.) CAMP4 Therapeutics Corporation (RSPI) CAMP4 Therapeutics Corporation (CGXP) CAMP4 Therapeutics Corporation (BGEN) CAMP4 Therapeutics Corporation (GTBP) CAMP4 Therapeutics Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 13463J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 62.75 Most Recent Split Date: (:1) Beta: 0.27 Market Capitalization: $215.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 51.05 EPS Growth vs. Year Ago Period: 64.52% vs. Previous Quarter: 31.25% Sales Growth vs. Year Ago Period: 18.84% vs. Previous Quarter: 37.48% ROE 09/30/26 - - 06/30/26 - -252.79 03/31/26 - -194.74 ROA 09/30/26 - - 06/30/26 - -85.65 03/31/26 - -95.64 Current Ratio 09/30/26 - - 06/30/26 - 4.70 03/31/26 - 6.15 Quick Ratio 09/30/26 - - 06/30/26 - 4.70 03/31/26 - 6.15 Operating Margin 09/30/26 - - 06/30/26 - -2,047.30 03/31/26 - -2,193.72 Net Margin 09/30/26 - - 06/30/26 - -2,543.74 03/31/26 - -2,193.72 Pre-Tax Margin 09/30/26 - - 06/30/26 - -2,543.74 03/31/26 - -2,193.72 Book Value 09/30/26 - - 06/30/26 - -0.01 03/31/26 - 0.60 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - 0.00

Powered by Zacks Investment Research ©